Skip to main content
NPCE
NASDAQ Life Sciences

NeuroPace Projects Q1 Revenue Above Expectations, Guiding $21M-$22M

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$15
Mkt Cap
$460.646M
52W Low
$7.563
52W High
$18.975
Market data snapshot near publication time

summarizeSummary

NeuroPace has issued first-quarter revenue guidance, projecting sales to be in the range of $21 million to $22 million. The indication that this guidance is above expectations suggests a positive outlook for the company's near-term financial performance. This update is material for a company of NeuroPace's size, as it directly impacts analyst models and investor sentiment regarding future growth. Traders will be watching for the actual Q1 earnings release to confirm these projections and for any further insights into the drivers of this anticipated revenue growth.

At the time of this announcement, NPCE was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460.6M. The 52-week trading range was $7.56 to $18.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


show_chartPrice Chart

Share this article

Copied!

feed NPCE - Latest Insights

NPCE
Mar 03, 2026, 4:54 PM EST
Filing Type: 10-K
Importance Score:
7
NPCE
Mar 03, 2026, 4:23 PM EST
Source: Wiseek News
Importance Score:
8
NPCE
Mar 03, 2026, 4:19 PM EST
Source: Dow Jones Newswires
Importance Score:
7